Advertisement

Related Videos

Welcome and Introduction to Vi3C

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Aug
09
Today In Oncology
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer
WHO Calls for Action in New Status Report on Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo